A recent study explored a new way to treat certain patients with head and neck cancer. The researchers tested whether ...

Cancers occurring in the mouth, nose, and throat are on the rise in the U.S., especially in younger people. About 60,000 new ...

One of the youngest victims of proposed NIH funding cuts would be six-year-old Cailen Vela of Michigan, who has a rare and ...

Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...

Proton arc therapy offers a superior dose distribution compared with existing state-of-the-art proton delivery techniques ...

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.

Mean dose to the tongue mucosa did not improve predictions of taste impairment during and after radiation therapy compared ...

HPV causes irritating warts, or lesions, on the back, front, or side of the tongue. Males have a higher risk of developing ...

Professor and surgeon Jason Hunt, MD, MS, FACS, has been named inaugural Chair of the Department of Otolaryngology – Head and ...

A physician-scientist at the University of Oklahoma is part of an international effort seeking new options for patients with head and neck cancer who cannot receive the standard chemotherapy drug ...

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with ...

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...